Abstract: There is provided a binder for a secondary battery anode, in which double-bond functional groups are selectively formed in a fluorine-based polymer by using an organic catalyst, and a cross-linked structure can be formed by the double bonds through only an electrode drying process without the introduction of a heterogeneous additive.

Abstract: Provided is a multilayer electronic component according to an example embodiment of the present disclosure including: a body including a dielectric layer and an internal electrode alternately disposed with the dielectric layer in a first direction, and including Ni; and an external electrode disposed on the body and connected to the internal electrode, wherein the external electrode includes a base electrode layer including Ni and Pd, and the internal electrode includes a first region, and a content of Pd included in the first region is greater than a content of Pd included in a remaining region, excluding the first region in the internal electrode.

Abstract: Proposed is a system for enabling a vehicle to perform a circuit mode. The system includes a communication unit provided in the vehicle to communicate with a vehicle-external device, a service providing server provided in the vehicle-external device to provide information related to a circuit, a controller which recognizes a current position of the vehicle by receiving a signal related to a vehicle position and which determines whether the vehicle arrives at the circuit based on the current position of the vehicle and the information related to the circuit received from the service providing server via the communication unit, the controller being configured to perform control for a circuit guide function that provides guide information related to the circuit mode and circuit driving when the vehicle enters the circuit mode, and an input/output unit outputting and providing the guide information to a driver by controlling the controller.

Abstract: A regenerative braking torque control system of an electric vehicle, includes a travel information setting section selects a regenerative braking level in response to a driver’s input and setting at least one driving mode among a plurality of driving modes, an in-vehicle information detector which detects in-vehicle information corresponding to a number and in-vehicle positions of occupants seated on vehicle seats, and a controller which allows driving to be performed according to the regenerative braking level selected by the travel information setting section, the controller transferring motor torque responsiveness according to the number and the in-vehicle positions of the occupants detected by the in-vehicle information detector to a motor controller for driving the vehicle by reflecting the motor torque responsiveness on regenerative braking torque.

Abstract: The present disclosure provides a method of providing guidance for use of electric power of an electric vehicle capable of limiting use of electric power in a vehicle-to-load (V2L) mode or providing various pieces of information on use of the electric power. The method includes receiving information on a set travel route to an electric vehicle charging station in the V2L mode, calculating battery energy requirements necessary for the vehicle to move from the current location to a charging station along the travel route, calculating available amount of energy in the V2L mode based on the battery energy requirements and the current amount of energy of a battery, calculating an available usage time of an electronic product based on electric power consumption per unit time of the electronic product and the available amount of energy, and displaying the available usage time of the electronic product through an information-providing device.

Abstract: An apparatus for controlling optimization of a charging amount of a battery for a vehicle charged with external power includes: a map storage, a position detector, and a controller to control the map storage and the position detector. The controller acquires a current position of the vehicle when a driver's desired charging setting value is input, acquires altitude information of topography corresponding to a driving path, calculates a gain charging amount in an uphill or downhill section on the driving path based on the altitude information, calculates an optimum charging setting value based on the driver's desired charging setting value and the gain charging amount, calculates a final target charging amount based on the optimum charging setting value and a current residual charging amount, and performs optimum charging of the battery.

Abstract: The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Abstract: The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Abstract: An apparatus for controlling optimization of a charging amount of a battery for a vehicle charged with external power includes: a map storage, a position detector, and a controller to control the map storage and the position detector. The controller acquires a current position of the vehicle when a driver's desired charging setting value is input, acquires altitude information of topography corresponding to a driving path, calculates a gain charging amount in an uphill or downhill section on the driving path based on the altitude information, calculates an optimum charging setting value based on the driver's desired charging setting value and the gain charging amount, calculates a final target charging amount based on the optimum charging setting value and a current residual charging amount, and performs optimum charging of the battery.

Abstract: The present invention relates to benzopyran derivatives substituted with a thioxobenzoxazole derivative, or pharmaceutically acceptable salts thereof, processes for preparing the same and a pharmaceutical composition containing the above as an effective ingredient Benzopyran derivatives substituted with thioxobenzoxazole derivatives, represented in <Formula 1>, have the function of protecting heart from ischemia-reperfusion both in vivo and in vitro, so that a pharmaceutical composition containing benzopyran derivatives substituted with thioxobenzoxoazole derivatives or pharmaceutically acceptable salts thereof of the present invention as an effective ingredient can be effectively used for the protection of tissues influenced by ischemia-reperfusion, for example, for the protection of heart, nervous cells, brain, retinal cells, storage organs, etc, and for the treatment of diseases caused by ischemia-reperfusion.

Abstract: The present invention relates to benzopyran derivatives substituted with secondary amines including tetrazole, method for preparing thereof and pharmaceutical compositions containing them. The compounds of the present invention can be used for protecting neuronal cells and brain damage; antioxidation; inhibiting NO generation; protecting heart; suppressing angiogenesis; protecting preserving organs such as kidney, heart and tissue, and protecting organs in major cardiovascular surgery.

Abstract: The present invention relates to furancarbonylguanidine derivatives, a preparation method thereof and a pharmaceutical composition comprising the same. Furancarbonylguanidine derivatives of the present invention inhibit NHE-1 (sodium-hydrogen exchanger isoform 1), which helps recovery of heart function damaged from ischemia/reperfusion and decreases myocardial infarction rate, indicating that they have protective effect on myocardial cells. Thus, furancarbonylguanidine derivatives of the present invention can be effectively used for the prevention and the treatment of ischemic heart diseases such as myocardial infarction, arrhythmia, angina pectoris, etc, and also a promising candidate for a heart protecting agent applied to reperfusion therapy including thrombolytics or cardiac surgery including coronary artery bypass graft, percutaneous transluminal coronary angioplasty, etc.

Abstract: The present invention relates to benzopyran derivatives substituted with a benzimidazole derivative, or pharmaceutically acceptable salts thereof, a preparation method of the same and pharmarceutical compositions containing them. Benzopyran derivatives substituted with a benzimidazole derivative, represented in Formula (1), have the function of protecting heart from ischemia-reperfusion without side effect like vasodilation, so that a pharmaceutical composition containing benzopyran derivatives substituted with a benzimidazole derivative or pharmaceutically acceptable salts thereof of the present invention as an effective ingredient can be effectively used for the protection of tissues influenced by ischemia-reperfusion, for example, for the protection of heart, nervous cells, brain, retinal cells, storage organs, etc. and for the treatment of diseases caused by ischemia-reperfusion.

Abstract: The present invention relates to benzopyran derivatives substituted with secondary amines including imidazole, their preparation, and pharmaceutical compositions containing them. The present invention is pharmacologically useful for the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and also pharmacologically useful in the protection of heart and neuronal cells against ischemia-reperfusion injury or preserving organs.

Abstract: The present invention relates to benzopyran derivatives substituted with a benzimidazole derivative, or pharmaceutically acceptable salts thereof, a preparation method of the same and pharmarceutical compositions containing them. Benzopyran derivatives substituted with a benzimidazole derivative, represented in Formula (1), have the function of protecting heart from ischemia-reperfusion without side effect like vasodilation, so that a pharmaceutical composition containing benzopyran derivatives substituted with a benzimidazole derivative or pharmaceutically acceptable salts thereof of the present invention as an effective ingredient can be effectively used for the protection of tissues influenced by ischemia-reperfusion, for example, for the protection of heart, nervous cells, brain, retinal cells, storage organs, etc. and for the treatment of diseases caused by ischemia-reperfusion.

Abstract: The present invention relates to benzopyran derivatives substituted with secondary amines including tetrazole, method for preparing thereof and pharmaceutical compositions containing them. The compounds of the present invention can be used for protecting neuronal cells and brain damage; antioxidation; inhibiting NO generation; protecting heart; suppressing angiogenesis; protecting preserving organs such as kidney, heart and tissue, and protecting organs in major cardiovascular surgery.

Abstract: The present invention relates to novel benzopyranyl heterocycle derivatives of the formula 1, process for preparation thereof and pharmaceutical use of the benzopyranyl heterocycle derivatives. The benzopyranyl heterocycle derivatives of the present invention can be used for protecting heart, brain, retina and neuronal cell from “ischemia-reperfusion” injury, treatment for diseases related to it and suppressing lipid peroxidation. Wherein R1, R2, R3, R4, n and * are each defined in specification.

Abstract: The present invention relates to novel benzopyranyl guanidine derivatives of the formula 1, process for preparation therof and pharmaceutical use of the benzopyranyl guanidine derivatives. The benzopyranyl guanidine derivatives of the present invention can be used for protecting heart, neuronal cell or brain damage, preserving organs, and also the benzopyranyl guanidine derivatives are pharmacologically useful for inhibiting NO generation, and for suppressing lipid peroxidation, angiogenesis or restenosis. Wherein R1, R2, R3, R4, R5, R6, n and * are each defined in specification.

Abstract: Substituted pyridyl imidazole derivatives of formula (I) inhibit effectively the action of angiotensin II and have a superior anti-hypertensive activity.

Abstract: Novel pyridyl imidazole derivatives of formula(I) inhibit effectively the action of angiotensin II and have a superior antihypertensive activity: ##STR1## wherein: A is a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl or alkenyl group, OR.sup.1 (wherein R.sup.1 is a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl or alkenyl radical), or NR.sup.2 R.sup.3 (wherein R.sup.2 and R.sup.3 are independently a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical);B is a group of the following formula ##STR2## D is a hydrogen; a halogen; a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl group which is optionally substituted with OH, a C.sub.1 -C.sub.4 alkoxy radical, CO.sub.2 R.sup.1, COR.sup.1, CON(R.sup.1).sub.2 or N(R.sup.1).sub.2, wherein R.sup.1 is the same as defined above; tetrazol-5-yl; a perfluoro-C.sub.1 -C.sub.4 alkyl group; or N(R.sup.1).sub.2, OR.sup.1, CO.sub.2 R.sup.1 or CON(R.sup.1).sub.2, wherein R.